Jose G. Monzon

3395 Hospital Dr NW
Calgary, AB T2N4N1, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 45 publications

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Corrigendum to "A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site" [Eur J Cancer (2026) 239 116709].

Journal: European journal of cancer (Oxford, England : 1990)

Published: April 17, 2026

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

A non-randomized phase 2 trial of pembrolizumab in untreated patients with carcinoma of unknown primary site.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 11, 2025

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

A phase I, open-label, multicentre, first-in-human study to evaluate safety, pharmacokinetics and efficacy of AMG 404, a PD-1 inhibitor, in patients with advanced solid tumours.

Journal: BMJ open

Published: May 02, 2025

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study.

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study.

Journal: Frontiers in oncology

Published: February 12, 2024

Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.

Management of Uveal Melanoma: Updated Cancer Care Alberta Clinical Practice Guideline.

Journal: Current oncology (Toronto, Ont.)

Published: September 25, 2023

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.

Treatment-Free Survival After Nivolumab vs Pembrolizumab vs Nivolumab-Ipilimumab for Advanced Melanoma.

Journal: JAMA network open

Published: June 23, 2023

Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.

Adjuvant Systemic Therapies for Resected Stages III and IV Melanoma: A Multi-Center Retrospective Clinical Study.

Journal: The oncologist

Published: April 11, 2023

NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.

NCI Rectal-Anal Task Force consensus recommendations for design of clinical trials in rectal cancer.

Journal: Journal of the National Cancer Institute

Published: February 17, 2023

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.

Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.

Journal: JAMA network open

Published: December 08, 2022

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.

Development and Validation of a Prognostic Risk Model for Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.

Journal: The oncologist

Published: August 26, 2022

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis.

Treatment of Unresectable Cutaneous Squamous Cell Carcinoma with Cemiplimab in a Patient on Dialysis.

Journal: Case reports in oncology

Published: July 21, 2022

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

CANDIED: A Pan-Canadian Cohort of Immune Checkpoint Inhibitor-Induced Insulin-Dependent Diabetes Mellitus.

Journal: Cancers

Published: November 01, 2021

Showing 1-12 of 45

Last Updated: 09/26/2026